Steven Paul

Steven Paul is our Interim President of R&D, a member of the Board of Directors and a Venture Partner at Third Rock Ventures. Dr. Paul has had a distinguished career in neuroscience with an extensive track record in CNS drug discovery and development. He joined Third Rock in 2010, where he serves as a senior advisor to the firm and participates in the ideation and development of new companies.

Dr. Paul also currently leads the Appel Alzheimer's Disease Research Institute at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of Discovery Research and Neuroscience Research. As President of the Lilly Research Laboratories, he was responsible for the company's overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities.

Prior to Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul has authored or co-authored more than 500 papers and book chapters